We are live on ! Find out more
EVFM

Evofem Biosciences, Inc. Common Stock

Delisted

EVFM was delisted on the 10th of August, 2022.

42 hedge funds and large institutions have $147M invested in Evofem Biosciences, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

17% more funds holding

Funds holding: 3642 (+6)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

24% less capital invested

Capital invested by funds: $194M → $147M (-$46.1M)

Holders
42
Holders Change
+6
Holders Change %
+16.67%
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
13
Reduced
10
Closed
4
Calls
$504K
Puts
Net Calls
+$504K
Net Calls Change
-$160K

EVFM Hedge Fund Activity: Q3 2019 in Review

42 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q3 2019, worth a combined $147M — down 24% from $194M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new EVFM positions and 4 closed out — a net gain of 6 holders — while 13 added to existing stakes and 10 trimmed.

The largest buyer was Jupiter Asset Management, opening a new position worth an estimated $6.34M. The largest seller was Woodford Investment Management, cutting an estimated $6.34M.

  • 42 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q3 2019, up from 36 in Q2 2019.
  • Funds reported $147M of Evofem Biosciences, Inc. Common Stock stock for Q3 2019, down 24% quarter-over-quarter.
  • 10 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q3 2019 and 4 closed out, a net change of +6 holders.
  • The largest Evofem Biosciences, Inc. Common Stock buyer in Q3 2019 was Jupiter Asset Management, an estimated $6.34M added.
  • The largest Evofem Biosciences, Inc. Common Stock seller in Q3 2019 was Woodford Investment Management, an estimated $6.34M sold.

Based on aggregated 13F filings for Q3 2019.